Ooops... Error 404

Sorry, but the page you are looking for doesn't exist.

Go to the homepage

Data show cardiometabolic benefits of Type 2 diabetes treatment

biotech Jim Cornall -
Sparrow Pharmaceuticals, Inc. has announced positive phase 2 clinical data for clofutriben, its lead investigational 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, in adults with...

Orphan Drug Designation for potential best-in-class ADC for sarcoma

biotech Jim Cornall -
SOTIO Biotech has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of...

FDA Breakthrough Therapy Designation for spinal muscular atrophy treatment

biotech Jim Cornall -
Biogen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular...

Servier acquiring Edgewise Therapeutics’ muscular dystrophy business

biotech Jim Cornall -
Servier has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. for up to $2.65bn, including an upfront payment...

Antibody fragment prevents haemorrhages associated with new Alzheimer’s treatments

biotech Jim Cornall -
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (Kisunla, from Eli Lilly and Company),...

Fast Track Designation for Lynch syndrome-associated cancers treatment

biotech Jim Cornall -
Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, has announced that the U.S. Food and Drug Administration (FDA)...

Positive data from linear IgA disease study

biotech Jim Cornall -
JJP Biologics has announced positive interim data from its ongoing phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89...

Base to Base biotech podcast 62: A new approach to strokes

biotech Jim Cornall -
This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method. Base to Base biotech...
- Advertisement -spot_img

Latest Articles

Load more